These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 648158)

  • 1. Circulating levels of norethindrone in women with a single silastic implant.
    Goyal V; Joshi UM; Naik VK
    Contraception; 1978 Apr; 17(4):375-82. PubMed ID: 648158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term contraception by a single silastic implant-D containing norethindrone acetate in women: a clinical evaluation.
    Takkar D; Anandalaxmi PN; Chandra VL; Bhatnagar S; Yadav HS; Laumas KR; Hingorani V; Krishna U; Mandleker A; Purandare VN; Goel V; Adatia A; Virker KD
    Contraception; 1978 Apr; 17(4):341-54. PubMed ID: 648156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subdermal norethindrone pellets -- a method for contraception?
    Odlind V; Moo-Young AJ; Gupta GN; Weiner E; Johansson ED
    Contraception; 1979 Jun; 19(6):639-48. PubMed ID: 487813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of fertility with oral medication.
    Diddle AW; Watts GF; Gardner WH; Williamson PJ
    West J Surg Obstet Gynecol; 1964; 72():222-9. PubMed ID: 12305556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term contraception by steroid releasing implants. VI. Serum concentrations of norethindrone in women bearing a single silastic implant releasing norethindrone acetate.
    Hillier SG; Jha P; Griffiths K; Laumas KR
    Contraception; 1977 Apr; 15(4):473-88. PubMed ID: 880821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of norethindrone acetate released from a single silastic implant on serum FSH, LH, progesterone and estradiol-17beta of women during first eight months of treatment.
    Rahman SA; Jha P; Laumas V; Jain AK; Dileepkumar ; Takkar D; Hingorani V; Laumas KR
    Contraception; 1977 Nov; 16(5):487-97. PubMed ID: 590011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norethisterone contraceptive microspheres.
    Rivera R; Alvarado G; Flores C; Aldaba S; Hernandez A
    J Steroid Biochem; 1987; 27(4-6):1003-7. PubMed ID: 3695501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous bioabsorbable pellets of norethindrone for contraception in women: Phase I. Clinical study.
    Gupta GN; Saxena BB; Landesman R; Ledger WJ
    Fertil Steril; 1984 May; 41(5):726-31. PubMed ID: 6714449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: noresthisterone oenanthate and medroxyprogesterone acetate. 2. Bleeding patterns and side effects.
    Contraception; 1978 May; 17(5):395-406. PubMed ID: 657807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate.
    Singh H; Uniyal JP; Jha P; Takker D; Murguesan K; Hingorani V; Laumas KR
    Acta Endocrinol (Copenh); 1982 Feb; 99(2):302-8. PubMed ID: 7058686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term contraception by steroid-releasing implants. II. A preliminary report on long-term contraception by a single silastic implant containing norethindrone acetate (ENTA) in women.
    Bhatnagar S; Srivastava UK; Takkar D; Chandra VL; Hingorani V; Laumas KR
    Contraception; 1975 May; 11(5):505-21. PubMed ID: 1139938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of the oral contraceptive estrogen burden by alternate day estrogen administration.
    Segre EJ; Henzl MR; Giner J; Scheel C; Bessler S
    Contraception; 1975 Aug; 12(2):155-74. PubMed ID: 1139955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical evaluation of injectable biodegradable contraceptive system.
    Beck LR; Ramos RA; Flowers CE; Lopez GZ; Lewis DH; Cowsar DR
    Am J Obstet Gynecol; 1981 Aug; 140(7):799-806. PubMed ID: 7020421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of norethisterone in women with subcutaneous implants of norethisterone acetate.
    Joshi JV; Naik VK; Joshi UM
    Indian J Med Res; 1979 Oct; 70():625-31. PubMed ID: 541006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contraceptive efficacy, pharmacokinetics, and safety of Annuelle biodegradable norethindrone pellet implants.
    Raymond EG; Singh M; Archer DF; Saxena BB; Baker J; Cole D
    Fertil Steril; 1996 Dec; 66(6):954-61. PubMed ID: 8941061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term study of oral contraception with norethindrone 2 mg. and mestranol 0.1 mg.
    Hutcherson WP; Schwartz HA; Weathers W
    Fertil Steril; 1966; 17(1):59-67. PubMed ID: 5901012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum norethindrone (NET) concentrations following intramuscular NET enanthate injection. Effect upon serum LH, FSH, estradiol and progesterone.
    Goebelsmann U; Stanczyk FZ; Brenner PF; Goebelsmann AE; Gentzschein EK; Mishell DR
    Contraception; 1979 Mar; 19(3):283-313. PubMed ID: 572279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical trial of norethisterone oenanthate (Norigest) injected every two months.
    Howard G; Blair M; Chen JK; Fotherby K; Muggeridge J; Elder MG; Bye PG
    Contraception; 1982 Apr; 25(4):333-40. PubMed ID: 7049569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Anovlar in gynaecological disorders and contraception.
    Shahani SM; Chiklikar A
    J Obstet Gynaecol India; 1968 Apr; 18(2):592-7. PubMed ID: 12331827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of norethindrone and individual metabolites in human plasma during short- and long-term administration of a contraceptive dosage.
    Braselton WE; Lin TJ; Ellegood JO; Mills TM; Mahesh VB
    Am J Obstet Gynecol; 1979 Jan; 133(2):154-60. PubMed ID: 369375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.